原发灶治疗前18F-FDG PET/CT代谢参数及纹理特征对儿童神经母细胞瘤的预后价值
回顾性纳入107例治疗前接受18F-FDG PET/CT的儿童神经母细胞瘤患者,测量原发灶4项代谢参数和43项纹理特征。中位随访34.3个月,多因素分析显示INRGSS M期、偏度、粗糙度、方差是PFS独立预测因子;INRGSS M期、MYCN扩增、代谢肿瘤体积是OS独立预测因子。
要点
- 原发灶PET纹理特征偏度>0.173、粗糙度>0.003及CT方差>103.837与PFS独立相关。
- INRGSS M期是PFS(HR=19.940)和OS(HR=7.704)的独立预测因子。
- 代谢肿瘤体积>138.788是OS独立预测因子(HR=3.930)。
核心结论
- 治疗前原发灶18F-FDG PET/CT的代谢参数和纹理特征可预测儿童神经母细胞瘤患者的生存。
研究设计与样本
- 回顾性纳入107例经病理诊断的儿童神经母细胞瘤患者,均行治疗前18F-FDG PET/CT,测量原发灶4项代谢参数和43项纹理特征,采用Cox比例风险回归和Kaplan-Meier法分析。
诊断标准与关键数值
- PFS多因素分析:INRGSS M期HR=19.940(95%CI 2.733-145.491,P=0.003);偏度>0.173(PET一阶特征)HR=2.938(95%CI 1.389-6.215,P=0.005);粗糙度>0.003(邻域灰度差矩阵)HR=0.253(95%CI 0.132-0.484,P<0.001);方差>103.837(CT一阶灰度直方图参数)HR=2.810(95%CI 1.160-6.807,P=0.022)。
- OS多因素分析:INRGSS M期HR=7.704(95%CI 1.031-57.576,P=0.047);MYCN扩增HR=3.011(95%CI 1.164-7.786,P=0.023);代谢肿瘤体积>138.788 HR=3.930(95%CI 1.317-11.727,P=0.014)。
- 中位随访34.3个月,45例(42.1%)出现肿瘤复发或进展,21例(19.6%)死于肿瘤。
临床应用与阅片要点
- 治疗前18F-FDG PET/CT原发灶的代谢参数和纹理特征可用于儿童神经母细胞瘤的预后评估。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
RATIONALE AND OBJECTIVES: Our study evaluated the prognostic value of the metabolic parameters and textural features in pretreatment 18F-Fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) of primary lesions for pediatric patients with neuroblastoma.
MATERIALS AND METHODS: In total, 107 pediatric patients with neuroblastoma who underwent pretreatment 18F-FDG PET/CT were retrospectively included and analyzed. All patients were diagnosed by pathology, and baseline characteristics and clinical data were collected. The four metabolic parameters and 43 textural features of 18F-FDG PET/CT of the primary lesions were measured. The prognostic significance of metabolic parameters and other clinical variables was assessed using Cox proportional hazards regression models. Differences in progression-free survival (PFS) and overall survival (OS) in relation to parameters were examined using the Kaplan-Meier method.
RESULTS: During a median follow-up period of 34.3 months, 45 patients (42.1%) experienced tumor recurrence or progression, and 21 patients (19.6%) died of cancer. In univariate Cox regression analysis, age, location of disease, International Neuroblastoma Risk Group Staging System (INRGSS) stage M, neuron-specific enolase (NSE), lactate dehydrogenase (LDH), four positron emission tomography (PET) metabolic parameters, and 33 textural features were significant predictors of PFS. In multivariate analysis, INRGSS stage M (hazard ratio [HR] = 19.940, 95% confidence interval [CI] = 2.733-145.491, P = 0.003), skewness (>0.173; PET first-order features; HR = 2.938, 95% CI = 1.389-6.215, P = 0.005), coarseness (>0.003; neighborhood gray-tone difference matrix; HR = 0.253, 95% CI = 0.132-0.484, P < 0.001), and variance (>103.837; CT first-order gray histogram parameters; HR = 2.810, 95% CI = 1.160-6.807, P = 0.022) were independent predictors of PFS. In univariate Cox regression analysis, gender, INRGSS stage M, MYCN amplification, NSE, LDH, two PET metabolic parameters, and five textural features were significant predictors of OS. In multivariate analysis, INRGSS stage M (HR = 7.704, 95% CI = 1.031-57.576, P = 0.047), MYCN amplification (HR = 3.011, 95% CI = 1.164-7.786, P = 0.023), and metabolic tumor volume (>138.788; HR = 3.930, 95% CI = 1.317-11.727, P = 0.014) were independent predictors of OS.
CONCLUSION: The metabolic parameters and textural features in pretreatment 18F-FDG PET/CT of primary lesions are predictive of survival in pediatric patients with neuroblastoma.
引用
- Wang G, Si Y, Liu J, et al. Prognostic Value of Metabolic Parameters and Textural Features in Pretreatment 18F-FDG PET/CT of Primary Lesions for Pediatric Patients with Neuroblastoma. Acad Radiol. 2023. PMID: 37748956. doi:10.1016/j.acra.2023.08.007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。